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For the 30-50% of patients with chronic hepatitis C who do not respond to a-interferon therapy there is no alternative 
treatment. Some previously untreated patients have shown a biochemical response to ribavirin, but the antiviral effects 
of this substance on a-interferon-resistant cases is largely unknown. Twelve patients with chronic hepatitis C who had 
not responded to a 6-12 month course of a-interferon were included in this study. Oral ribavirin was administered 
at a dose of 16 mg/kg per day for 6 or 9 months. Aminotransferase levels had not significantly changed uring inter- 
feron therapy but decreased significantly during ribavirin treatment (mean alanine aminotransferase at baseline, 
102 ± 18 IU/I vs. 55 ± 14 IU/I at 6 months; P = 0.0001). Aminotransferase levels became normal in 6 cases (50'V,,), 
significantly decreased in 3 patients (25'Vo), and did not significantly change in the remaining 3cases (25'V,,). All patients 
with normalized aminotransferase values relapsed after ribavirin was discontinued and aminotransferase activity 
returned to pretreatment levels. Before therapy serum hepatitis C virus RNA was detected by polymerase chain reac- 
tion in 10 cases. None of them had cleared viral RNA when tested following 3, 6 and 9 months of ribavirin therapy. 
Side-effects were mild and reversible. In conclusion, about half of the patients with chronic hepatitis C who are 
unresponsive to a-interferon show a clear-cut biochemical response after 6-9 months of ribavirin administration. 
However, ribavirin does not clear circulating hepatitis C virus RNA and relapses occur after withdrawal. Therefore, 
since ribavirin alone does not appear to suppress viral replication, despite its biochemical effect, further studies hould 
be made in combination with other antiviral substances. 
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Hepatitis C virus (HCV) is the etiological agent of 
most, if not all, parenterally acquired cases of non-A 
non-B hepatitis (1-4). Acute infection usually remains 
subclinical, but unfortunately the disease evolves to 
chronicity in more than 50% of the patients (1,5,6). 
Chronic carriers of HCV have a high risk of developing 
cirrhosis, and some will eventually develop hepatocellu- 
lar carcinoma (5,7,8). Serological studies in volunteer 
blood donors suggest that 0.5-1.2% of the general pop- 
ulation in the developed world may be infected with 
HCV (1,3,4,9). At present a-interferon (alFN) is the 
only therapy which has been extensively evaluated in the 
treatment of chronic hepatitis C (10). Of the patients 
with chronic hepatitis C, 50-70% respond to a lFN and 
show a normalization of aminotransferase levels and an 
improvement in the liver lesion. Response to alFN is 
usually accompanied by a clearance of serum HCV 
RNA (11). However, since 50% of the responders re- 
lapse after alFN discontinuation, the long-term benefit 
from this treatment remains limited to 20-30% of the 
patients. At present, there is no alternative therapy for 
chronic hepatitis C cases unresponsive to alFN. 
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Ribavirin( 1 -B- D-ribo furanosyl- 1,2,4-triazole-3-car bo-
xamide) is a synthetic nucleoside analogue structurally 
similar to guanosine, xanthosine, and pyrazofurin (12). 
Ribavirin displays antiviral activity against a wide range 
of DNA and RNA viruses, including some members of 
the flaviviridae family, to which HCV has been provi- 
sionally assigned (12). This substance also inhibits the in 
vitro replication of hepatitis A, B, and D (delta) viruses 
(13-15). Ribavirin induces an alteration of the nucleo- 
tide pools and inhibits the normal transcription of 
messenger RNA. It is rapidly transported into cells and 
converted by cellular enzymes, to mono-, di- and tri- 
phosphate derivatives, which then inhibit viral nucleic 
acid synthesis (16,17). Ribavirin has been approved for 
use as an aerosol for infants with serious infections due 
to respiratory syncytial virus. It has also been used oral- 
ly or intravenously in the treatment of chronic hepatitis 
B (18), human immunodeficiency virus infection (19), 
influenza virus infection (20), and Lassa fever (21). 
Recently, a pilot study of ribavirin in 10 patients with 
chronic hepatitis C showed a significant decrease in 
aminotransferase levels during ribavirin administration 
(22). Unfortunately, all responders elapsed shortly after 
ribavirin withdrawal. Side-effects were mild and 
reversible. 
The aim of this study was to assess the activity of 
ribavirin in patients with chronic hepatitis C unrespon- 
sive to ~IFN. The biochemical nd virological responses 
were assessed with serial determination of aminotrans- 
ferase levels, and by the detection of serum HCV RNA. 
Methods 
Twelve patients (4 men and 8 women) with 
histologically proven chronic hepatitis C (10 with active 
cirrhosis) were included in this study. Mean age was 57.1 
years (range, 35-70 years). All patients had raised 
aminotransferases l vels for more than 6 months, and 
antibodies against HCV were repeteadly detected in all 
patients by a second-generation enzyme-linked immun- 
osorbent assay (Ortho Diagnostic Systems, Raritan, 
N J). Four patients had previously received transfusions, 
and the remainder had no known percutaneous ri k fac- 
tor. Other causes of chronic active hepatitis were care- 
fully excluded. All were negative for antibodies to the 
human immunodeficiency virus, and other causes of 
immunodeficiency were also excluded. All 12 patients 
had been previously treated with lymphoblastoid alFN 
(Wellferon, Gayoso-Wellcome, Madrid, Spain) at doses 
of 3 × 106 units daily or 3 times/week for 6 (n = 5) or 
12 months (n = 7). Aminotransferases were unchanged 
during and after otlFN therapy in all cases. The 
minimum alFN-free period before ribavirin administra- 
tion was 6 months. Ribavirin (Virazole, 1CN-Hubber 
SA, Barcelona, Spain) was taken orally every 8 h for a 
total daily dose of 16 mg/kg. Due to the absence of signi- 
ficant side-effects all patients completed the treatment 
schedule. Nine patients received ribavirin for 6 months, 
and the remaining 3 patients received it for 9 months. 
Patients were followed-up for a mean of 4.6 ± 1.9 
months (range, 3-9) after treatment was stopped. 
Aminotransferases (upper normal limit (UNL) of alan- 
ine aminotransferase (ALT): 30 IU/I), alkaline phospha- 
tase, 3,glutamyltranspeptidase, bilirubin, hemoglobin, 
leucocytes, platelets, serum creatinine, and uric acid 
were assessed every 10 days for the first 2 months, and 
monthly thereafter, including follow-up. Presence of 
serum HCV RNA was investigated by reverse transcrip- 
tion of RNA extracted from 50-p.l samples and amplifi- 
cation of the cDNA by 'nested' polymerase chain 
reaction (PCR) (see below), before ribavirin administra- 
tion (month 0), and at months 3, 6, and 9 of ribavirin 
therapy. Serum samples were stored at -80°C until PCR 
testing. 
The PCR technique was performed as described 
elsewere (23,24) using primer sequences derived from 
the highly conserved 5' non-coding region of a cDNA 
clone of a Japanese isolate (25) (outer primers: CI5, sen- 
se, 5' GTATCTCGAGGCGACACTCCACCATAGAT 
and C16, antisense, 5 'ATACTCGAGGTGCACGGT- 
CTACGAGACCT corresponding to nucleotide posi- 
tions 1-19 and 323-303, respectively, and inner 
primers: C17, sense, 5'CCACCATAGATCTCTCCC- 
CTGT and Ci8, antisense, 5'CACTCTCGAGCACC- 
CTATCAGCGAGT, corresponding to nucleotide 
positions 10-31 and 296-271, respectively). The second 
PCR round enhances sensitivity of the technique, 
theoretically allowing the detection of one single copy of 
the virus, while a unique PCR round followed by gel 
electrophoresis and ethidium bromide staining detects 
approximately 100-200 copies. Positivity in the first 
round PCR, or only after the second round was used as 
a semiquantitative method to assess the antiviral effect 
of ribavirin. Carry over contaminations were avoided by 
strictly applying the measures described by Kwok and 
Higuchi (26). 
All patients gave informed consent and the trial was 
approved by the Local Ethics Committee. 
Statistical analysis was performed using paired and 
unpaired Student's t-tests, and the Wiicoxon test. Re- 
sults are presented as mean ± S.E.M. 
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Results 
As shown in Fig. l, mean ALT levels had not changed 
significantly during cdFN therapy, (mean ALT: 
103 + 12, l l9 4- 23, and l l4 + 27, at months 0, 3, and 
at 6-12 months, respectively). In contrast, ALT levels 
significantly decreased uring ribavirin administration; 
month 0 :102  4- 18, month 3 :69  + 18, month 6: 
55 ± 14; month 0 vs. month 3, P < 0.01 and month 0 
vs. month 6, P = 0.0001 (Fig. 2). Aminotransferase 
values became normal in 6 patients (50%) (complete re- 
sponse), decreased to less than twice the UNL in 3 cases 
(25%) (partial response), and did not substantially 
change in the remaining 3 patients (25%) (no response). 
The mean interval to normalization of aminotransfer- 
ases in the 6 complete responders was 2.6 months, 
(range, 1-5 months). Pre-treatment aminotransferase 
levels were lower in complete responders (n = 6) than in 
non-responders and partial responders (n = 6) (79 ± 16 
vs. 123 ± 25), although this did not reach statistical 
significance (Fig. 2). 
One complete responder and two non-responders 
received ribavirin for 9 months, and the remaining pati- 
ents for 6 months. All six complete responders relapsed 
after therapy and aminotransferase activities returned to 
pretreatment levels (month l (after stopping ribavirin): 
48.16 ± 9.45; month 2:53.5 4- 9.44; month 3:77.66 
4- 23.65). Aminotransferases did not change after treat- 
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Fig. 1. Evolution of ALT levels during the first 6 months of cdFN 
therapy. No significant changes were observed. The shadowed area 
corresponds to the normal range of ALT. Results are presented as 
mean ± S.E.M. 
ALT 
U/I 
J. CAMPS et al. 
Evolution of ALT levels during ribavirin treatment 
175 ~- Ribavirin = 
loo 
75 
5o 
0 1 2 3 4 5 6 
Months 
• No response and partial response group (n=6) 
• All patients (n:,12} 
• Complete response group (n=6) 
Fig. 2. Evolution of ALT concentrations during ribavirin therapy. 
The whole group of patients, the complete response group, and the 
group of non-responders and partial responders are separately 
represented. 
ment in non-responders and increased to pretreatment 
levels in partial responders. 
Before ribavirin therapy, HCV RNA was detected in 
l0 cases (83%). None of these patients cleared HCV 
RNA during therapy when tested 3, 6 and 9 months 
after beginning treatment. HCV RNA was detectable at 
months 3 and 6 in ! of the 2 cases without detectable 
viral RNA before treatment. One patient with yon 
Willebrand's disease who had been transfused uring 
delivery of a normal baby, and developed clear-cut post- 
transfusion on-A, non-B hepatitis, but in whom HCV 
RNA was never detected espite seroconversion to anti- 
HCV, also showed a complete biochemical response to 
ribavirin administration. Seventy percent of the baseline 
samples howed a positive band on ethidium bromide 
staining after the first PCR round, while the remainder 
were detected only after the second round of amplifica- 
tion. This percentage did not change significantly when 
samples obtained at 3 and 6 months after ribavirin 
administration, were tested for HCV RNA (Table l). 
Response to ribavirin was not related to baseline PCR 
results; 4 out of the 5 non-responders or partial 
responders were positive by the first round PCR and 3 
out of the 5 complete responders were also positive by 
first round PCR (Table l). 
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TABLE 1 
Results of the detection of serum HCV RNA before and during ribavirin treatment in patients with chronic HCV infection resistant o alfa 
interferon 
Complete responders Non-responders and partial responders 
Patient No. Baseline Month 3 Month 6 Patient No. Baseline Month 3 Month 6 
1 ++ ++ ++ 7 + + + 
2 ++ ++ ++ 8 ++ ++ + 
3 ++ + ++ 9 - + + 
4 - - - 10 ++ ++ ++ 
5 + ++ + I1 ++ + ++ 
6 + + ++ 12 ++ ++ + 
Plus and minus marks indicate a positive or negative PCR result: +, positive only after second round PCR (see Methods section); ++, positive 
after first round PCR; - ,  negative PCR result. 
Side-effects were always mild and reversible. Two 
patients complained of mild abdominal discomfort dur- 
ing the first week of therapy, and most (10/12, 83%) 
developed mild asymptomatic hemolytic anemia (hemo- 
globin levels between 10 and 12 g/dl), and 5 asymp- 
tomatic hyperuricemia (6.5-9 mg/dl). Hemoglobin and 
uric acid levels had returned to normal values in all cases 
1 month after ribavirin therapy was discontinued. 
Discussion 
To our knowledge this is the first study which 
evaluates treatment for chronic hepatitis C resistant o 
alFN. Ribavirin was well tolerated in all cases, and a 
significant decrease in ALT levels was observed in 75% 
of the patients. Although half the patients normalized 
aminotransferase concentrations, ribavirin did not seem 
to effect viral replication since none of the patients 
cleared serum HCV RNA as detected by PCR. 
Moreover, not even a partial inhibition of HCV replica- 
tion could be demonstrated as determined by first and 
second round PCR results (27,28). Since response to 
cdFN is usually associated with serum HCV RNA 
clearance (11), the mechanism by which ribavirin in- 
duces a biochemical response is not known. However, 
quantitative PCR methods, (i.e., serial dilutions of the 
samples), should be made to examine a possible partial 
inhibition of HCV replication. Ribavirin could interfere 
with the mechanisms of liver cell injury (perhaps by 
reducing the cytopathic effect of HCV), without affec- 
ting viral replication. Ribavirin has also been shown to 
diminish the primary antibody responses and memory 
cell generation to T-dependent and T-independent anti- 
gens in vivo (29). Thus, ribavirin, in addition to its anti- 
viral effect, might induce a biochemical response by 
acting as an immunosuppressor drug. However, this 
immunosupressant effect has not been consistently 
demonstrated in vivo, and at low doses ribavirin could 
enhance certain immunological responses (30). The rea- 
son why half the patients howed a complete biochemi- 
cal response to ribavirin is not known, since viral 
replication was persistant in all cases. Since mutations of 
the plus-stranded RNA Sindbis virus have been shown 
to lead to resistance to ribavirin therapy (31), some 
mutants of HCV could also be resistant o ribavirin. 
The results of this study suggest hat some chronic 
hepatitis C patients who are unresponsive to ~IFN may 
benefit from ribavirin therapy, l~ibavirin could 
therefore constitute an alternative treatment for these 
patients. However, whether the biochemical response is 
accompanied by an improvement of the liver necroin- 
flammatory lesion must be studied. The relapse of all 
responders after therapy suggests that for long-term 
benefit patients should receive ribavirin for years or 
indefinitely. The persistence of viremia in all cases is 
consistent with the post-therapy relapses observed in all 
complete responders (22). A sinergistic in vitro effect of 
ribavirin and t~IFN on the replication of infectious 
feline peritonitis virus has been described (32). 
Therefore, a combination of ribavirin with t~IFN or 
other antivirals hould be investigated in these patients. 
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